Boston Scientific reveals federal probe of BridgePoint buy, sales
August 7, 2014 by Arezu Sarvestani
BridgePoint Medical Inc.
Boston Scientific reveals federal probe of BridgePoint buy, sales
Boston Scientific (NYSE:BSX) informed investors this week that it’s under investigation by the U.S. Attorney for the District of New Jersey over a cardiology devices company acquired 2 years ago.
Boston Scientific to buy BridgePoint Medical
Boston Scientific (NYSE:BSX) said it agreed to buy BridgePoint Medical for an undisclosed amount, adding the Minneapolis-based medical device company’s technology for treating blocked blood vessels in the heart to its stable of interventional cardiology tools.
Neoprobe presses past controversy, submits Lymphoseek NDA| Regulatory Roundup
Cancer diagnostics firm Neoprobe Corp. (NYSE Amex:NEOP) pressed past the controversy surrounding its Lymphoseek radiopharmaceutical and submitted a new drug application for FDA review.
The Dublin, Ohio-based company hopes to win clearance for Lymphoseek for use in intraoperative lymphatic mapping, a surgical procedure that identifies and biopsies lymph nodes for traces of cancer.
Pain wars: Industry giants battle to lead the house of pain
Bovie Medical names new president, shuffles board | Personnel moves
Bovie Medical Corp. (NYSE:BVX) announced a flurry of personnel moves in its corner office and board room.
The company said current president and CEO Andrew Makrides will relinquish his title of president but keep his position as chief executive. J. Robert Saron, the firm’s chief sales and marketing officer, will assume the role of president. Saron formerly served as Bovie’s CEO from 1994 through 1998.
Medtronic readies billion-dollar debt offering | Funding roundup
Medtronic Inc. (NYSE:MDT) is looking to drum up $1 billion through a debt offering.
The Fridley, Minn.-based medical device giant announced a registered offering of $500 million worth of its 2.625 percent senior notes, due 2016, and $500 million of its 4.125 percent senior notes due in 2021.
BridgePoint drums up $9 million
BridgePoint Medical Inc. raised $9.1 million from the sale of equity, according to documents filed with the Securities & Exchange Commission.
The Plymouth, Minn.-based company is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels.
The new round brings BridgePoint’s total fundraising over the last two months to $10 million.
BridgePoint Medical raises $1 million
BridgePoint Medical Inc. raised $1 million from the sale of debt and stock warrants, according to documents filed with the federal Securities and Exchange Commission.
The company, based in Plymouth, Minn., is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels.
